Table 4.
Relation between Genetic Polymorphism and Clinical Response.
| The frequency | Response | P value | |||
|---|---|---|---|---|---|
| Favorable N (row %) | Unfavorable N (row %) | ||||
| ABCG2.34 G>A | GG | 83 (81.4%) | 57 (69.5%) | 25 (30.5%) | 0.01* |
| GA | 17 (16.7%) | 7 (41.2%) | 10 (58.8%) | ||
| AA | 2 (2%) | 2 (100.0%) | |||
| ABCG2. 421C>A | CC | 91 (89.2%) | 55 (60.4%) | 36 (39.6%) | 0.20 |
| CA | 10 (9.8%) | 8 (88.9%) | 1 (11.1%) | ||
| AA | 1 (1%) | 1 (100.0%) | |||
| ABCB1.2677 G>A/T | GG | 101(99%) | 64 (64.0%) | 36 (36.0%) | 0.37 |
| GA | 1 (1%) | 1 (100.0%) | |||
| AA | 0 (0%) | ||||
| TT | 0 (0%) | ||||
| ABCB1.1236 C>T | CC | 17 (16.7%) | 10 (58.8%) | 7 (41.2%) | 0.47 |
| CT | 49 (48%) | 34 (69.4%) | 15 (30.6%) | ||
| TT | 36 (35.3%) | 20 (57.1%) | 15 (42.9%) | ||
| ABCB1.3435C>T | CC | 38 (37.3%) | 21 (56.8%) | 16 (43.2%) | 0.51 |
| CT | 48 (47.1%) | 33 (68.8%) | 15 (31.3%) | ||
| TT | 16 (15.7%) | 10 (62.5%) | 6 (37.5%) | ||
| SLCO1B3.334 T>G | TT | 7 (7.1%) | 1 (16.7%) | 5 (83.3%) | 0.03* |
| TG | 31 (31.3%) | 23 (74.2%) | 8 (25.8%) | ||
| GG | 61 (61.6%) | 39 (63.9%) | 22 (36.1%) | ||
| CYP3A5 | *1 | 6 (5.9%) | 3 (50.0%) | 3 (50.0%) | 0.83 |
| *1/3 | 28 (27.5%) | 18 (64.3%) | 10 (35.7%) | ||
| *3 | 68 (66.7%) | 43 (64.2%) | 24 (35.8%) | ||
G, guanine; C, cytosine; A, adenine; T, thiamine; ABCB1, multidrug resistant gene; ABCG2, breast cancer resistant gene; SLCO1B3, uptake gene; CYP3A5, cytochrome metabolizing gene.
*
p value is significant ≤ 0.05.